DBV Fundamental Analysis - DBV TECHNOLOGIES SA

Fundamental Rating

DBV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. DBV may be in some trouble as it scores bad on both profitability and health. DBV is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year DBV has reported negative net income.

DBV had a negative operating cash flow in the past year.

DBV had negative earnings in each of the past 5 years.

DBV had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

DBV has a Return On Assets of -85.56%. This is in the lower half of the industry: DBV underperforms 73.49% of its industry peers.

The Return On Equity of DBV (-142.22%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-85.56%
ROE	-142.22%
ROIC	N/A

ROA(3y)-84.27%

ROA(5y)-75.7%

ROE(3y)-172.64%

ROE(5y)-138.93%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

DBV has a Gross Margin of 91.34%. This is amongst the best in the industry. DBV outperforms 85.54% of its industry peers.

DBV's Gross Margin has declined in the last couple of years.

DBV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	91.34%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, DBV has more shares outstanding

The number of shares outstanding for DBV has been increased compared to 5 years ago.

Compared to 1 year ago, DBV has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -2.53, we must say that DBV is in the distress zone and has some risk of bankruptcy.

DBV's Altman-Z score of -2.53 is on the low side compared to the rest of the industry. DBV is outperformed by 63.86% of its industry peers.

A Debt/Equity ratio of 0.08 indicates that DBV is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.08, DBV is in the better half of the industry, outperforming 67.47% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-2.53

ROIC/WACCN/A

WACC7.76%

2.3 Liquidity

A Current Ratio of 2.45 indicates that DBV has no problem at all paying its short term obligations.

DBV has a Current ratio (2.45) which is in line with its industry peers.

DBV has a Quick Ratio of 2.45. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.

DBV has a better Quick ratio (2.45) than 61.45% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.45
Quick Ratio	2.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.66% over the past year.

Looking at the last year, DBV shows a very strong growth in Revenue. The Revenue has grown by 224.69%.

DBV shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.50% yearly.

EPS 1Y (TTM)43.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)224.69%

Revenue growth 3Y11.73%

Revenue growth 5Y0.5%

Sales Q2Q%N/A

3.2 Future

DBV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.26% yearly.

The Revenue is expected to grow by 75.93% on average over the next years. This is a very strong growth

EPS Next Y-36.93%

EPS Next 2Y-15.64%

EPS Next 3Y22.79%

EPS Next 5Y16.26%

Revenue Next Year-55.09%

Revenue Next 2Y271.45%

Revenue Next 3Y438.04%

Revenue Next 5Y75.93%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DBV. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBV. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as DBV's earnings are expected to grow with 22.79% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-15.64%

EPS Next 3Y22.79%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for DBV!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

DBV TECHNOLOGIES SA

FRA:DBV (12/5/2025, 7:00:00 PM)

2.27

+0.02 (+0.67%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-28 2025-10-28/amc

Earnings (Next)03-23 2026-03-23/amc

Inst Owners61.98%

Inst Owner ChangeN/A

Ins Owners0.11%

Ins Owner ChangeN/A

Market Cap81.60M

Revenue(TTM)15.73M

Net Income(TTM)-122.55M

Analysts80

Price Target4.02 (77.09%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	25.01
P/FCF	N/A
P/OCF	N/A
P/B	1.1
P/tB	1.1
EV/EBITDA	N/A

EPS(TTM)-0.65

EYN/A

EPS(NY)-0.87

Fwd EYN/A

FCF(TTM)-2.1

FCFYN/A

OCF(TTM)-2.1

OCFYN/A

SpS0.09

BVpS2.06

TBVpS2.06

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-85.56%
ROE	-142.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	91.34%
FCFM	N/A

ROA(3y)-84.27%

ROA(5y)-75.7%

ROE(3y)-172.64%

ROE(5y)-138.93%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

F-Score2

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	42.61%
Cap/Sales	8.26%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.45
Quick Ratio	2.45
Altman-Z	-2.53

F-Score2

WACC7.76%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)25.42%

Cap/Sales(5y)23.37%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)43.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next Y-36.93%

EPS Next 2Y-15.64%

EPS Next 3Y22.79%

EPS Next 5Y16.26%

Revenue 1Y (TTM)224.69%

Revenue growth 3Y11.73%

Revenue growth 5Y0.5%

Sales Q2Q%N/A

Revenue Next Year-55.09%

Revenue Next 2Y271.45%

Revenue Next 3Y438.04%

Revenue Next 5Y75.93%

EBIT growth 1Y-31.72%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year11.6%

EBIT Next 3Y16.74%

EBIT Next 5YN/A

FCF growth 1Y0.85%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y0.45%

OCF growth 3YN/A

OCF growth 5YN/A

DBV TECHNOLOGIES SA / DBV.DE FAQ

What is the fundamental rating for DBV stock?

ChartMill assigns a fundamental rating of 3 / 10 to DBV.DE.

Can you provide the valuation status for DBV TECHNOLOGIES SA?

ChartMill assigns a valuation rating of 1 / 10 to DBV TECHNOLOGIES SA (DBV.DE). This can be considered as Overvalued.

What is the profitability of DBV stock?

DBV TECHNOLOGIES SA (DBV.DE) has a profitability rating of 1 / 10.

What is the expected EPS growth for DBV TECHNOLOGIES SA (DBV.DE) stock?

The Earnings per Share (EPS) of DBV TECHNOLOGIES SA (DBV.DE) is expected to decline by -36.93% in the next year.

DBV TECHNOLOGIES SA (DBV.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

DBV TECHNOLOGIES SA / DBV.DE FAQ

What is the fundamental rating for DBV stock?

Can you provide the valuation status for DBV TECHNOLOGIES SA?

What is the profitability of DBV stock?

What is the expected EPS growth for DBV TECHNOLOGIES SA (DBV.DE) stock?